Quantcast
Published On: Fri, Jan 10th, 2014

FDA approves Mekinist in combination with Tafinlar for advanced melanoma

PRESS RELEASE

This week the U.S. Food and Drug Administration approved Mekinist (trametinib) in combination with Tafinlar (dabrafenib) to treat patients with advanced melanoma that is unresectable (cannot be removed by surgery) or metastatic (late-stage).
 
Global Dispatch 200x119In May 2013, the FDA approved both drugs as single agents to treat patients with unresectable or metastatic melanoma. Melanoma is the most aggressive type of skin cancer and is the leading cause of death from skin disease. The National Cancer Institute estimated that 76,690 Americans would be diagnosed with melanoma and 9,480 would die from the disease in 2013.
 
Mekinist and Tafinlar are used to block signaling in different sites of the same molecular pathway that promotes cancer cell growth. They are specifically indicated as a combination therapy for patients with melanoma whose tumors express gene mutations called BRAF V600E and V600K. The BRAF protein is involved in the regulation of normal cell growth, but it is mutated in approximately half of melanomas arising from the skin.  
 
“Mekinist and Tafinlar are the first drugs approved for combination treatment of melanoma,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Their development for combination use is based on the strong understanding of the biological pathways of the disease. This approval illustrates the value of continuing to study drugs in combination for clinical development.”
 
The safety and effectiveness of Mekinist in combination with Tafinlar were demonstrated in a clinical trial of 162 participants with unresectable or metastatic melanoma with the BRAF V600E or V600K mutation, most of whom had not received prior therapy. Participants received either Mekinist in combination with Tafinlar or Tafinlar as a single agent until their melanoma progressed or side effects became intolerable.
 
Results showed that 76 percent of participants treated with Mekinist in combination with Tafinlar had their cancer shrink or disappear (objective response) that lasted an average of 10.5 months. In contrast, 54 percent of participants treated with Tafinlar as a single agent experienced objective responses that lasted an average of 5.6 months. Clinical trials are ongoing to determine whether Mekinist in combination with Tafinlar improves survival.
 
The most common side effects reported in participants receiving Mekinist in combination with Tafinlar included fever, chills, tiredness, rash, nausea, vomiting, diarrhea, abdominal pain, peripheral edema (swelling in the hands and feet), cough, headache, joint pain, night sweats, decreased appetite, constipation and muscle pain. During clinical testing, the incidence and severity of fever increased when Mekinist was used in combination with Tafinlar.
 
Serious side effects included bleeding, clot formation, heart failure, skin problems and eye problems. One of the serious side effects of Tafinlar—the development of a new squamous cell carcinoma of the skin—was reduced when the drug was used in combination with Mekinist; this is consistent with the biology of the effects of these two drugs on the targeted molecular pathway. The incidence of squamous cell carcinoma of the skin in this trial was 7 percent with the combination compared to 19 percent with single agent Tafinlar. Other clinically significant side effects include kidney injury.
 
Women of child bearing potential should be advised that Mekinist and Tafinlar can cause birth defects in a developing fetus.  Men and women should also be advised that Mekinist and Tafinlar treatment may cause infertility.
 
The FDA approved the combination of Mekinist and Tafinlar under the agency’s accelerated approval program, which allows the FDA to approve a drug to treat a serious disease based on clinical data showing that the drug has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit to patients. This program provides earlier patient access to promising new drugs while the company conducts confirmatory clinical trials. The FDA also reviewed this combination of drugs under the agency’s priority review because they demonstrated the potential to be a significant improvement in safety or effectiveness in the treatment of a serious condition.
 
Mekinist and Tafinlar are marketed by GlaxoSmithKline, based in Research Triangle Park, N.C.
 
On the DISPATCH: Headlines  Local  Opinion

Subscribe to Weekly Newsletter

* indicates required
/ ( mm / dd ) [ALL INFO CONFIDENTIAL]

About the Author

- Writer, Co-Founder and Executive Editor of The Global Dispatch. Robert has been covering news in the areas of health, world news and politics for a variety of online news sources. He is also the Editor-in-Chief of the website, Outbreak News Today and hosts the podcast, Outbreak News Interviews on iTunes, Stitcher and Spotify Robert is politically Independent and a born again Christian Follow @bactiman63

Displaying 13 Comments
Have Your Say
  1. JohnetteMetzgar says:

    I am welcome to the decision of FDA for approved the mekinist .
    http://www.zimbio.com/Bodybuilding/articles/a5HwITbZK6Y/Right+Time+Building+Muscle

  2. Mekinist Plus Tafinlar OK’d for Late-Stage Melanoma – WebMD | Rss News Desk | Daily News Magazine says:

    […] approves drug combo to treat advanced melanomaUPI.comScience World Report -The Global Dispatchall 77 news […]

  3. Mekinist Plus Tafinlar OK'd for Late-Stage Melanoma – WebMD | RHN says:

    […] approves drug combo to treat advanced melanomaUPI.comScience World Report -The Global Dispatchall 77 news […]

  4. Mekinist Plus Tafinlar OK'd for Late-Stage Melanoma – WebMD | HNP says:

    […] approves drug combo to treat advanced melanomaUPI.comScience World Report -The Global Dispatchall 77 news […]

  5. Mekinist Plus Tafinlar OK'd for Late-Stage Melanoma – WebMD | RHN says:

    […] OKs 2-Drug Combo Treatment for Advanced MelanomaPhilly.comScience World Report -The Global Dispatchall 77 news […]

  6. Mekinist Plus Tafinlar OK'd for Late-Stage Melanoma – WebMD | HNP says:

    […] OKs 2-Drug Combo Treatment for Advanced MelanomaPhilly.comScience World Report -The Global Dispatchall 77 news […]

  7. US FDA approves two-drug combination for advanced melanoma – Xinhua | Weight Loss Diet Plan says:

    […] of Mekinist (trametinib) …FDA approves drug combo to treat advanced melanomaUPI.comFDA approves Mekinist in combination with Tafinlar for advanced melanomaThe Global DispatchFDA OKs 2-Drug Combo Treatment for Advanced MelanomaHealthDayall 75 news […]

  8. FDA approves drug combo to treat advanced melanoma – UPI.com | Weight Loss Diet Plan says:

    […] and …FDA Approves First Combination Therapy for Treatment of MelanomaScience World ReportFDA approves Mekinist in combination with Tafinlar for advanced melanomaThe Global DispatchFDA OKs 2-Drug Combo Treatment for Advanced MelanomaHealthDayMedical Xpressall 72 […]

  9. US FDA approves two-drug combination for advanced melanoma – Xinhua | Amazing News says:

    […] of Mekinist (trametinib) …FDA approves drug combo to treat advanced melanomaUPI.comFDA approves Mekinist in combination with Tafinlar for advanced melanomaThe Global DispatchFDA OKs 2-Drug Combo Treatment for Advanced […]

  10. US FDA approves two-drug combination for advanced melanoma – Xinhua | Medical Websites says:

    […] melanomaUPI.comFDA Approves First Combination Therapy for Treatment of MelanomaScience World ReportFDA approves Mekinist in combination with Tafinlar for advanced melanomaThe Global DispatchHealthDayall 75 news […]

  11. FDA approves drug combo to treat advanced melanoma – UPI.com | Amazing News says:

    […] and …FDA Approves First Combination Therapy for Treatment of MelanomaScience World ReportFDA approves Mekinist in combination with Tafinlar for advanced melanomaThe Global DispatchFDA OKs 2-Drug Combo Treatment for Advanced […]

  12. FDA approves drug combo to treat advanced melanoma – UPI.com | HNP says:

    […] and …FDA Approves First Combination Therapy for Treatment of MelanomaScience World ReportFDA approves Mekinist in combination with Tafinlar for advanced melanomaThe Global DispatchFDA OKs 2-Drug Combo Treatment for Advanced […]

  13. FDA approves drug combo to treat advanced melanoma – UPI.com | RHN says:

    […] and …FDA Approves First Combination Therapy for Treatment of MelanomaScience World ReportFDA approves Mekinist in combination with Tafinlar for advanced melanomaThe Global DispatchFDA OKs 2-Drug Combo Treatment for Advanced […]

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

like_us_on_facebook

 

The Global Dispatch Facebook page- click here

Movie News Facebook page - click here

Television News Facebook page - click here

Weird News Facebook page - click here 

DISPATCH RADIO

dispatch_radio

THE BRANDON JONES SHOW

brandon_jones_show-logo

Archives